Concepedia

J. A. Morgan

JA

Statistics

Publications

8

Citations

214

H-Index

8

Active since

1978

Affiliations

Dana-Farber Cancer Institute(Current)

Fox Chase Cancer Center

J. A. Morgan is an author at Dana-Farber Cancer Institute specializing in medicine, oncology, and pharmacology.

Publications per year

1978–2011

8

Publications

8

Charcot‐Marie‐Tooth disease with Leber optic atrophy

J. G. McLeod, Phillip A. Low, J. A. Morgan · Neurology · 1978 · 46 citations

, , +14

An open-label phase II study of the Hsp90 inhibitor ganetespib (STA-9090) in patients (pts) with metastatic and/or unresectable GIST.

G. D. Demetri, Michael C. Heinrich, Bartosz Chmielowski et al. · Journal of Clinical Oncology · 2011 · 40 citations

, , +3

Randomized phase II study of trabectedin in patients with liposarcoma and leiomyosarcoma (L-sarcomas) after failure of prior anthracylines (A) and ifosfamide (I)

J. A. Morgan, Axel Le Cesne, Sant P. Chawla et al. · Journal of Clinical Oncology · 2007 · 38 citations

, , +15

Phase I dose-escalation study of the SRC and multi-kinase inhibitor BMS-354825 in patients (pts) with GIST and other solid tumors

T. R. J. Evans, J. A. Morgan, Annick D. Van den Abbeele et al. · Journal of Clinical Oncology · 2005 · 31 citations

, , +17

Continuous daily dosing (CDD) of sunitinib (SU) in patients with metastatic soft tissue sarcomas (STS) other than GIST: Results of a phase II trial

Mary Louise Keohan, J. A. Morgan, David R. D’Adamo et al. · Journal of Clinical Oncology · 2008 · 17 citations

, , +16

1–5 of 8